Bringing pharmacomicrobiomics to the clinic through well‐designed studies. Issue 10 (9th August 2022)

• Record Type: Journal Article
• Authors: Steiner, Heidi E.; Patterson, Hayley K.; Giles, Jason B.; Karnes, Jason H.
• Is Part Of: Clinical and translational science. Volume 15:Issue 10(2022)
• Page Start: 2303
• Page End: 2315
• Publication Date: 2022-08-09
• Subjects: Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; 616.027
• DOI: 10.1111/cts.13381
• Languages: English
• ISSNs: 1752-8054

Abstract

Abstract: Pharmacomicrobiomic studies investigate drug‐microbiome interactions, such as the effect of microbial variation on drug response and disposition. Studying and understanding the interactions between the gut microbiome and drugs is becoming increasingly relevant to clinical practice due to its potential for avoiding adverse drug reactions or predicting variability in drug response. The highly variable nature of the human microbiome presents significant challenges to assessing microbes' influence. Studies aiming to explore drug‐microbiome interactions should be well‐designed to account for variation in the microbiome over time and collect data on confounders such as diet, disease, concomitant drugs, and other environmental factors. Here, we assemble a set of important considerations and recommendations for the methodological features required for performing a pharmacomicrobiomic study in humans with a focus on the gut microbiome. Consideration of these factors enable discovery, reproducibility, and more accurate characterization of the relationships between a given drug and the microbiome. Furthermore, appropriate interpretation and dissemination of results from well‐designed studies will push the field closer to clinical relevance and implementation.